12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IC43: Phase II/III started

Intercell began a double-blind, European Phase II/III trial to compare its IC43 Pseudomonas aeruginosa vaccine given twice within a 7-day period plus standard of care (SOC) vs. placebo plus SOC in 800 ventilated intensive care...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >